ArticleAnnals of surgical oncology2026
TMPRSS4 Expression Predicts Survival and Benefit from Neoadjuvant Chemotherapy in Pancreatic Cancer.
Article in Annals of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTransmembrane serine protease 4 (TMPRSS4) is known to promote epithelial-mesenchymal transition, invasion, and metastasis in pancreatic cancer and has been linked to chemotherapy resistance. However, whether TMPRSS4 status affects the efficacy of neoadjuvant chemotherapy (NAC) in pancreatic ductal adenocarcinoma (PDAC) remains unclear. This study aimed to evaluate the clinical significance of TMPRSS4 expression in patients with resected PDAC, focusing on its prognostic impact and interaction with NAC.
methodsThis retrospective study included consecutive patients who underwent curative-intent resection for PDAC between November 2015 and October 2024. Expression of TMPRSS4 was assessed immunohistochemically. The study examined its associations with clinicopathologic factors, survival, and NAC efficacy.
resultsAmong 154 patients screened, the study included 152 patients with evaluable TMPRSS4 expression. In 95 patients (63 %), TMPRSS4 expression was positive. The TMPRSS4-positive tumors were significantly larger than the TMPRSS4-negative tumors. The 5-year overall survival rate was significantly lower in the TMPRSS4-positive group than in the TMPRSS4-negative group. Larger tumor size, TMPRSS4 positivity, lymph node metastasis, and non-adjuvant chemotherapy were independently associated with poor overall survival. Among the patients with resectable PDAC (n = 119), NAC significantly improved survival for the TMPRSS4-positive patients, whereas no significant benefit was observed for the TMPRSS4-negative patients. A significant interaction was observed between TMPRSS4 expression and NAC (hazard ratio, 0.25; 95 % confidence interval, 0.07-0.88; p = 0.032).
conclusionsIn PDAC, TMPRSS4 expression was associated with poor prognosis. The survival benefit of NAC appeared to be greater for the TMPRSS4-positive patients, suggesting that TMPRSS4 may serve as a potential exploratory marker for treatment stratification.
Indexed as
Identifiers
42467155What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.